The identification of combinatorial therapeutic approaches with
BCR inhibitors in B cell malignancies

a 2017

The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies

PAVLASOVÁ, Gabriela; Kateřina MUSILOVÁ; Václav ŠEDA; Kateřina ČERNÁ; Eva VOJÁČKOVÁ et al.

Základní údaje

Originální název

The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies

Autoři

PAVLASOVÁ, Gabriela; Kateřina MUSILOVÁ; Václav ŠEDA ; Kateřina ČERNÁ; Eva VOJÁČKOVÁ; Veronika SVOBODOVÁ a Marek MRÁZ

Vydání

AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer, 2017

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.365

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/17:00098134

Organizační jednotka

Středoevropský technologický institut

ISSN

DOI

https://doi.org/10.1158/1538-8514.SYNTHLETH-A34

UT WoS

000412270800024

Klíčová slova anglicky

BCR inhibitor; B cell; CLL

Štítky

rivok

Změněno: 6. 11. 2017 09:43, Mgr. Eva Špillingová

Anotace

V originále

It was shown that BCR inhibitors such as ibrutinib interrupt microenvironmental interactions and mobilize malignant B cells of chronic lymphocytic leukemia (CLL) from immune niches into the blood stream. It has been suggested that this mobilization will sensitize malignant B cells to other drugs, providing a possibility to introduce synthetically lethal combinations of drugs with an acceptable toxicity profile. This might be limited to a subgroup of CLL patients with specific underlying molecular mechanisms of disease biology or reaction to BCR inhibitors. The aim of this study was to test for the effect of ibrutinib on the expression of genes and activity of pathways that could be potentially targeted by clinically available drugs to achieve highly potent combinations.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

PAVLASOVÁ, Gabriela; Kateřina MUSILOVÁ; Václav ŠEDA; Kateřina ČERNÁ; Eva VOJÁČKOVÁ; Veronika SVOBODOVÁ a Marek MRÁZ. The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies. In AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer. 2017. ISSN 1535-7163. Dostupné z: https://doi.org/10.1158/1538-8514.SYNTHLETH-A34.

@proceedings{1394261,
   author = {Pavlasová, Gabriela and Musilová, Kateřina and Šeda, Václav and Černá, Kateřina and Vojáčková, Eva and Svobodová, Veronika and Mráz, Marek},
   booktitle = {AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer},
   doi = {https://doi.org/10.1158/1538-8514.SYNTHLETH-A34},
   keywords = {BCR inhibitor; B cell; CLL},
   language = {eng},
   title = {The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies},
   url = {http://mct.aacrjournals.org/content/16/10_Supplement/A34},
   year = {2017}
}

TY  - CONF
ID  - 1394261
AU  - Pavlasová, Gabriela - Musilová, Kateřina - Šeda, Václav - Černá, Kateřina - Vojáčková, Eva - Svobodová, Veronika - Mráz, Marek
PY  - 2017
TI  - The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies
KW  - BCR inhibitor
KW  - B cell
KW  - CLL
UR  - http://mct.aacrjournals.org/content/16/10_Supplement/A34
L2  - http://mct.aacrjournals.org/content/16/10_Supplement/A34
N2  - It was shown that BCR inhibitors such as ibrutinib interrupt microenvironmental interactions and mobilize malignant B cells of chronic lymphocytic leukemia (CLL) from immune niches into the blood stream. It has been suggested that this mobilization will sensitize malignant B cells to other drugs, providing a possibility to introduce synthetically lethal combinations of drugs with an acceptable toxicity profile. This might be limited to a subgroup of CLL patients with specific underlying molecular mechanisms of disease biology or reaction to BCR inhibitors. The aim of this study was to test for the effect of ibrutinib on the expression of genes and activity of pathways that could be potentially targeted by clinically available drugs to achieve highly potent combinations.
ER  -

PAVLASOVÁ, Gabriela; Kateřina MUSILOVÁ; Václav ŠEDA; Kateřina ČERNÁ; Eva VOJÁČKOVÁ; Veronika SVOBODOVÁ a Marek MRÁZ. The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies. In \textit{AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer}. 2017. ISSN~1535-7163. Dostupné z: https://doi.org/10.1158/1538-8514.SYNTHLETH-A34.

Přehled o publikaci